CER Daily Newsfeed

Empagliflozin, Dapagliflozin Comparably Reduce AKI, CKD Risks in Diabetes Population

(1/22, Natasha Persaud, Renal & Urology News) reports “Empagliflozin and dapagliflozin are equally effective in reducing the long-term risks of acute kidney injury (AKI) and chronic kidney disease (CKD) in adults with type 2 diabetes, according to findings from a comparative effectiveness study.” Full

ICER Announces Launch Price and Access Report

(1/22, John O’Brien, Linked In Post) comments “...NPC repeatedly called for the discontinuation of the flawed UPI report; we’re glad to see it go. The Fair Access report purported to hold payers accountable for providing ‘fair’ patient access but never really had the data or visibility to do so. It’s premature to judge the new report before seeing the methodology, though I’m skeptical ICER can overcome the significant blind spots within what we’ve heard thus far.” Full

Trump Urged by Democratic Senators to Keep Lowered Drug Prices

(1/21, Madison Muller, Bloomberg) reports “...Trump should use his deal-making skills to ‘flat out reject any request to end negotiations from giant pharmaceutical makers that have spent decades putting profits over patients,’ Democratic Senators Elizabeth Warren of Massachusetts and Ron Wyden of Oregon and Independent Bernie Sanders of Vermont wrote in a letter to the president seen by Bloomberg. ‘There is no legal basis for any pause, and allowing giant pharmaceutical companies to pressure you into one would dramatically increase costs for over 60 million Medicare beneficiaries and betray your own campaign promises,’ the lawmakers said.” Subscription Required

NAACOS Applauds Bipartisan House Bill on Value-Based Data Reporting

(1/21, Mark Hagland, Healthcare Innovation) reports “The nation’s preeminent association supporting the development of accountable care organizations (ACOs) on Jan. 21 expressed satisfaction over the bipartisan introduction of legislation into the U.S. House of Representatives that would delay a requirement imposed by the Centers for Medicare & Medicaid Services (CMS) for ACOs to report electronic clinical quality measures...” Full

UK: AstraZeneca Receives NICE Recommendations for Lung Cancer Drugs Tagrisso and Imfinzi

(1/22, Emily Kimber, PMLiVE) reports “AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi (durvalumab) in NHS patients across England and Wales.” Full

India to Set up New Health Tech Assessment Centres to Help Policymakers Use Resources Optimally

(1/21, Priyanka Sharma, Live Mint) reports “...‘The resource centres will be responsible for undertaking HTA studies, capacity building activities like workshops, training programmes and online courses,’ the DHR said in a notice inviting expressions of interest from interested institutes. ‘These centres will also be conducting HTA sensitisation workshops for state/central government health programmes and facilitate adoption of HTA recommendations by state/central government programmes.’” Full